Affinium Pharmaceuticals, Inc.
33Patents
13Active
33Granted
42Portfolio score
Filing activity: Jan 28, 1997 → Jul 6, 2010 · 13 expiring within 5 years
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US6730684B1 | Fab I inhibitors | Chemistry; Metallurgy | 26 | Expired |
| US6573272B1 | Antibacterial compounds | Human Necessities | 26 | Expired |
| US6846819B1 | Fab I inhibitors | Emerging Cross-Sectional Technologies | 24 | Expired |
| US6951729B1 | High throughput screening method for biological agents affecting fatty acid biosynthesis | Physics | 22 | Expired |
| US7048926B2 | Methods of agonizing and antagonizing FabK | Emerging Cross-Sectional Technologies | 22 | Expired |
| US7049310B2 | Fab I inhibitors | Emerging Cross-Sectional Technologies | 22 | Expired |
| US6673941B2 | Disubstituted imidazoles useful in the treatment of bacterial infections | Chemistry; Metallurgy | 22 | Expired |
| US6765005B2 | Fab I inhibitors | Human Necessities | 21 | Expired |
| US7250424B2 | Fab I inhibitors | Emerging Cross-Sectional Technologies | 21 | Expired |
| US6762201B1 | Fab I inhibitors | Chemistry; Metallurgy | 21 | Expired |
| US6821746B2 | Methods of screening for FabK antagonists and agonists | Chemistry; Metallurgy | 21 | Expired |
| US6995254B1 | Polynucleotide encoding the enoyl-acyl carrier protein reductase of Staphylococcus aureus, FAB I | Human Necessities | 20 | Expired |
| US6964970B2 | Antibacterial compounds | Human Necessities | 18 | Expired |
| US7557125B2 | Fab I inhibitors | Emerging Cross-Sectional Technologies | 17 | Active |
| US7524843B2 | Fab I inhibitors | Emerging Cross-Sectional Technologies | 17 | Active |
| US7790716B2 | Fab I inhibitors | Emerging Cross-Sectional Technologies | 13 | Active |
| US7741339B2 | Fab I inhibitors | Emerging Cross-Sectional Technologies | 10 | Active |
| US8450307B2 | Therapeutic agents, and methods of making and using the same | Chemistry; Metallurgy | 9 | Active |
| US8263613B2 | Salts, prodrugs and polymorphs of fab I inhibitors | Chemistry; Metallurgy | 9 | Active |
| US7790709B2 | Heterocyclic compounds, methods of making them and their use in therapy | Chemistry; Metallurgy | 9 | Expired |
| US7879872B2 | Compositions comprising multiple bioactive agents, and methods of using the same | Human Necessities | 8 | Active |
| US8153652B2 | Fab I inhibitors | Emerging Cross-Sectional Technologies | 8 | Active |
| US8173646B2 | FAB I inhibitors | Emerging Cross-Sectional Technologies | 6 | Active |
| US8318720B2 | Acrylamide derivatives as Fab I inhibitors | Chemistry; Metallurgy | 6 | Active |
| US6753172B1 | FabI | Human Necessities | 5 | Expired |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.